Celebrex returns to the tube
Pfizer resumes direct-to-consumer advertising of its COX-2 inhibitor Celebrex (celecoxib) for the first time since the company agreed to suspend DTC ads for Celebrex following the release of a study showing an increase in cardiovascular risk (1"The Pink Sheet" Jan. 3, 2005, p. 19). The new ad emphasizes Celebrex's CV risk as similar to that associated with NSAIDs ibuprofen and naproxen. "If you look closer, FDA requires all these NSAID pain relievers, including Celebrex, to have the same cardiovascular warning. Any prescription NSAID, including Celebrex, may increase the risk of heart attack or stroke," the commercial states...
You may also be interested in...
Pfizer is revising Celebrex and Bextra professional promotions at FDA's request to include suggestions that physicians consider alternative therapies on an individual patient basis
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.